Novo Nordisk inks $2.1B oral obesity drug deal / Beckers
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance
Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 22 stories in 13 days
Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours / ESMO
esmo - Findings from the PYNNACLE study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, March 2, 2026, 2:22 am / permalink 19973 / 9 stories in 14 days
Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #healthcarefinance
Monday, March 2, 2026, 12:23 am / permalink 19968 / 2 stories in 14 days
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 16 days
First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results / Medical Express
medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…
#healthcare #biotech #drugdevelopment #infanthealth
Saturday, February 28, 2026, 1:22 am / permalink 19931 / 2 stories in 16 days
Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 16 days
Novartis to build $23B radioligand therapy site / Beckers
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 16 days
Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 16 days
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance
Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 16 days
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment
Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 18 days
More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 20 days
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 20 days
Gilead to acquire cell therapy manufacturer for $7.8B / Beckers
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology
Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 21 days
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO
esmo - Findings from the KEYNOTE-905/EV-303 study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 21 days
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 21 days
A novel C. diff vaccine shows promise / Beckers
Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety
Saturday, February 21, 2026, 7:21 am / permalink 19520 / 2 stories in 23 days
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront / Endpoints
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, February 21, 2026, 6:22 am / permalink 19517 / 2 stories in 23 days
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 23 days
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks / Nature
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
#healthcare #publichealth #biotech #drugdevelopment #fda #medicaldevices
Saturday, February 21, 2026, 2:22 am / permalink 19513 / 13 stories in 23 days
'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice / LiveScience
livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety
Friday, February 20, 2026, 5:22 pm / permalink 19489 / 3 stories in 24 days